Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Geron is a biopharmaceutical company developing therapeutic products for cancer and chronic degenerative diseases based on telomerase and human embryonic stem cell (hESC) technologies. The company has no approved products and relies on research collaborations and licensing for revenue.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2007 |
Six Months Ended June 30, 2006 (Restated) |
|---|---|---|---|
| Total Revenues | $889 | $1,805 | $1,369 |
| Operating Expenses | $17,655 | $34,973 | $23,639 |
| Loss from Operations | $(16,766) | $(33,168) | $(22,270) |
| Net Loss | $(13,985) | $(12,818) | $(10,189) |
| Net Loss Applicable to Common Stockholders | $(13,985) | $(16,479) | $(10,189) |
| Cash and Cash Equivalents (Balance Sheet) | $126,943 (as of June 30, 2007) | ||
| Marketable Securities (Balance Sheet) | $90,011 (as of June 30, 2007) | ||
| Accumulated Deficit | $(415,573) (as of June 30, 2007) |
Cash Flow (Six Months Ended June 30, 2007):
- Net cash used in operating activities: $(13,118)
- Net cash used in investing activities: $(12,620)
- Net cash provided by financing activities: $16,799
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 32% for the six months ended June 30, 2007, compared to the prior year period. This was driven by increased revenue from collaborative agreements ($597k vs. $166k), primarily due to reimbursements from the joint venture TA Therapeutics, Ltd. (TAT).
- Expense Increase: Operating expenses rose significantly, with Research and Development (R&D) expenses increasing 46% year-over-year for the six-month period ($27.3M vs. $18.7M). Increases were attributed to higher personnel costs, stock-based compensation, and manufacturing/clinical trial costs for the telomerase inhibitor GRN163L and vaccine GRNVAC1.
- Derivative Accounting: The company recorded a significant unrealized gain on derivatives of $14.8 million for the six months ended June 30, 2007, compared to $8.1 million in the prior year. This was largely due to the reclassification of certain warrant liabilities to equity following amendments to warrant agreements in March 2007.
- Joint Venture Consolidation: Effective June 16, 2007, Geron consolidated the results of its Hong Kong joint venture, TAT, after acquiring control (75% voting interest) following a restructuring agreement.
Guidance, Outlook, and Risks
- Liquidity: Management estimates existing capital resources, interest income, and equipment financing will fund operations through at least December 2008. However, the company expects to incur additional operating losses and will require substantial additional capital in the future.
- Outlook: R&D expenses are expected to increase in the coming year due to clinical trials for GRN163L and GRNVAC1, continued hESC program development, and the inclusion of TAT operating expenses.
- Risks:
- Regulatory Approval: No products are currently approved; success depends on obtaining FDA and other regulatory approvals, which is uncertain and costly.
- Capital Needs: The company has a history of losses and an accumulated deficit of $415.6 million. Future funding is required, and additional equity financing could result in significant dilution.
- Intellectual Property: Ongoing patent oppositions in Europe (e.g., with Pharmexa) and reexaminations of licensed WARF patents in the U.S. create uncertainty regarding proprietary rights.
- Stock-Based Compensation: Significant non-cash expenses related to stock options and restricted stock awards continue to impact operating results.
Key Facts for Investor Verification
- Runway: Verify the sufficiency of the $217.5 million in cash and marketable securities to fund operations through the projected December 2008 date, considering the high burn rate.
- Derivative Reclassification: Confirm the impact of the March 2007 warrant amendments on the balance sheet (reclassification of $22.6M from liabilities to equity) and the resulting non-cash gains.
- TAT Consolidation: Review the terms of the June 15, 2007 restructuring agreement with the Biotechnology Research Corporation (BRC) to understand the future funding obligations and revenue recognition related to the TAT joint venture.
- Clinical Progress: Monitor the status of Phase I/II clinical trials for GRN163L (telomerase inhibitor) and GRNVAC1 (telomerase vaccine), as these are the primary drivers of future R&D spend and potential revenue.
- Patent Litigation: Track the outcomes of the European patent oppositions with Pharmexa and the U.S. reexamination of WARF patents, as these are critical to the company's hESC and telomerase platforms.